DARTMOUTH ENTREPRENEURIAL NETWORK OF DC


  • Home
  • CEO Roundtable: Rachel K. King, D'81, Chief Executive Officer, GlycoMimetics

CEO Roundtable: Rachel K. King, D'81, Chief Executive Officer, GlycoMimetics

  • 01 May 2014
  • 6:00 PM - 8:00 PM
  • Fish and Richardson, 1425 K St NW, Washington, DC 20005. Metro: McPherson Square (Orange and Blue Lines) or Farragut North (Red Line)

Registration


Registration is closed

CEO ROUNDTABLE with Rachel K. King, D'81, Chief Executive Officer, GlycoMimetics


At the May 1, 2014 meeting of the Dartmouth Entrepreneurial Network of DC, Rachel K. King, D'81, Chief Executive Officer, GlycoMimetics, will talk about the entrepreneurship cycle, from “Idea to IPO.”

Rachel was recently been named one of the "TOP 10 women in Biotech" list by FierceBiotech.

Biography

Before co-founding GlycoMimetics, Mrs. King was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Mrs. King came to NEA after serving as a Senior Vice President of Novartis Corporation. Before joining Novartis, Mrs. King spent ten years with Genetic Therapy, Inc. (GTI), a biotechnology company, where she served in a number of roles as part of the executive team, through that company’s initial public offering and later acquisition by Novartis. After the acquisition by Novartis, she served as CEO of Genetic Therapy, which was then a wholly owned subsidiary of Novartis. Mrs. King also worked previously at ALZA Corporation in Palo Alto, California and at Bain and Company in Boston.

She received her B.A. degree from Dartmouth College and her M.B.A. from Harvard Business School. Mrs. King currently serves as Chair of the Board of the Biotechnology Industry Organization (BIO).  At BIO, she is also on the Executive Committee and is a former Chair of the Emerging Companies Governing Body. She is also Chair of the Maryland Life Sciences Advisory Board appointed by Governor Martin O’Malley.

GlycoMimetics is a Gaithersburg, MD-base company developing a lead drug for vaso-occlusive crisis of sickle cell disease.

Powered by Wild Apricot Membership Software